Showing 6351-6360 of 7750 results for "".
- Positive Interim Data Seen with Sirnaomics Ltd’s STP705 in BCChttps://practicaldermatology.com/news/positive-interim-data-seen-with-sirnaomics-ltds-stp705-in-bcc/2461089/Interim data from a Phase 2 clinical trial of Sirnaomics Ltd’s STP705 shows a dose response with complete response, as well as improved or stable cosmetic result with no significant cutaneous skin reactions among patients with cutaneous basal cell carcinoma (BCC). The new data als
- Cyspera Launches New Three-Step System to Treat Hyperpigmentationhttps://practicaldermatology.com/news/cyspera-launches-new-three-step-system-to-treat-hyperpigmentation/2461083/Scientis is launching Cyspera Intensive System, a new three-product system designed to improve hyperpigmentation. Cysteamine inhibits several steps in the melanogenesis pathway while also working as antioxidant to protect against free radicals. The
- Study: More Than Half of Postmenopausal Women Experience Female Pattern Hair Losshttps://practicaldermatology.com/news/study-more-than-half-of-postmenopausal-women-experience-female-pattern-hair-loss/2461079/More than half of postmenopausal women experience female pattern hair loss, according to a studypublished online in Menopause. In a new cross-sectional study involving 178 women seen at a menopause clinic, researchers aimed to evaluate the prevalence of female pat
- Third Harmonic Bio Launches with an Eye on Chronic Urticariahttps://practicaldermatology.com/news/third-harmonic-bio-launches-with-an-eye-on-chronic-urticaria/2461078/Third Harmonic Bio is launching with the close of a Series B financing campaign. With total capital to date of $155 million, the company plans to fund development of its lead candidate, THB001, through the next phase of human studies for the initial indication of chronic urticaria. 
- FDA Green-lights Casio’s DZ-D100 Dermocamera and the DZ-S50 Scopehttps://practicaldermatology.com/news/fda-green-lights-casios-dz-d100-dermocamera-and-the-dz-s50-scope/2461076/The U.S. Food and Drug Administration (FDA) has cleared Casio’s
- Study: Oral Dutasteride Outperforms Other Male Hair Loss Treatmentshttps://practicaldermatology.com/news/study-oral-dutasteride-outperforms-other-male-hair-loss-treatments/2461073/The top-ranking hair loss treatment for men is dutasteride (Avodart) capsules, at a dose of 0.5 milligrams a day, according to a new meta-analysis of 23 studies published online Feb. 2 in
- Juvederm Volbella XC Scores FDA Nod for Undereye Hollowshttps://practicaldermatology.com/news/juvederm-volbella-xc-scores-fda-nod-for-undereye-hollows/2461071/The US Food and Drug Administration has given its nod to Allergan Aesthetics, Juvederm Volbella XC for improvement of infraorbital hollows in adults over the age of 21. Per FDA requirement for this new indication, Allergan Aesthetics is providing a product training
- Leadership Changes Take Place at SkinCeuticalshttps://practicaldermatology.com/news/leadership-changes-at-skinceuticals/2461069/Stephanie Kramer is now SkinCeutical’s Global General Manager, and Amy Sloan is the Head of SkinCeuticals U.S, the company reports Sloan brings 15 years of global and U.S. beauty industry experience - 10 of those years with SkinCeuticals - to the role of Head o
- National Foundation for Cancer Research Taps NYC Dermatologist for Board Seathttps://practicaldermatology.com/news/national-foundation-for-cancer-research-taps-dermatologist-for-board-seat/2461065/The National Foundation for Cancer Research (NFCR) has announced that New York dermatologist Dr. Karen Burke and two others will be joining the board. NFCR was founded in 1973 to support cancer research and public education relating to the prevention, early diagnosis, better treatments
- Dupixent Update: Medication Shows Promise in Five Inflammatory Diseaseshttps://practicaldermatology.com/news/dupixent-update-medication-shows-promise-in-five-inflammatory-diseases/2461063/Dupixent (dupilumab) performed well across five diseases with underlying type 2 inflammation. The five diseases include eosinophilic esophagitis, chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. Additionally, positive result